International Hellenic University

 Join the IHU Students!

Alexandros-Anastasios Garyfallos

ALEXANDROS GARYFALLOS

Professor in Internal Medicine - Rheumatology, School of Medicine, Aristotle University of Thessaloniki

 

Education

1981: Aristotle University of Thessaloniki, M.D.

1985: Aristotle University of Thessaloniki, Ph.D., Internal Medicine

 

Positions and Employment

1988-90: Consultant, Greek National Health System, 1st Medical Department of the Central Medical Hospital of Thessaloniki

1990: Lecturer in Internal Medicine, 4th Dept of Internal Medicine, Aristotle University of Thessaloniki

1994: Research Fellow, Rheumatology Unit of Guy’s Hospital, London

1995: Assistant Professor in Internal Medicine, 4th Dept of Internal Medicine, Aristotle University of Thessaloniki

1996-present: Head of the Rheumatology Unit, 4th Dept of Internal Medicine, Aristotle University of Thessaloniki

2002: Associate Professor in Internal Medicine and Clinical Immunology, 4th Dept of Internal Medicine, Aristotle University of Thessaloniki

2008: Professor in Internal Medicine and Clinical Immunology, 4th Dept of Internal Medicine, Aristotle University of Thessaloniki

2011-2013: Vice President, Medical School, Aristotle University of Thessaloniki

2012-present: Chairman, 4th Dept of Internal Medicine, Aristotle University of Thessaloniki

2013-present: President, Medical School, Aristotle University of Thessaloniki

 

Honors and Awards

  • Elected member of the Sanate of Aristotle University of Thessaloniki for 7 years
  • Elected member of the Disciplinary Board of the Medical Association of Thessaloniki, 2002-2004
  • Member Organizing Committee, 11th Mediterranean Congress of Rheumatology, Crete, September 2005
  • Member Organizing Committee, 26th European Workshop for Rheumatology Research, Crete, February 2006
  • Member of the Committee of the Postgraduate Program in Rheumatology in Greece organized by the 7th Greek Medical Departments, 2007-present
  • Member of the Scientific Committee of more than 15 Greek Congresses

 

Clinical Research Experience

2017

IV

Randomized, double-blind, placebo-controlled Multicenter study of subcutaneous secukinumab to demonstrate efficacy in the treatment of Achilles tendon intheseitis for up to 1 year in adult patients With active psoriatic arthritis (PsA) and axonal spindle arthritis (axSpA) (ACHILLES)

PI

2016

IV

A randomized, double-blind, multicenter study with a test substance to assess the efficacy at week 52 of subcutaneously administered monotherapy Secukinumab compared to subcutaneously administered adalimumab monotherapy in patients with active psoriatic arthritis

PI

2016

IV

Evaluation of Stelara (Ustekinumab) and anti-TNFa agent therapies in patients with psoriatic arthritis in routine clinical practice.

PI

2016

III

A phase 3, multicenter, randomized, double blind, placebo controlled parallel group study, followed by an active treatment phase to evaluate the efficacy and safety of Apremilast (CC-10004) in the treatment of subjects with active BEHCET'S disease.

PI

2013

IV

Epidemiological characteristics of inflammatory diseases mediated by interleukin-1 and their response to the current medication in Greece (ILIAD)

PI

2013

II

An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with mild to moderate systemic lupus erythematosus

PI

2012

IV

An open, prospective, non-interventional, observational study for safety and efficacy of certolizumab pegol in patients with rheumatoid arthritis in daily practice in Greece

 

2011

IV

A three-year follow-up study of patients with moderate to severe rheumatoid arthritis who were prescribed HUMIRA, in Greece

PI

2008

IV

The evaluation of the safety of etanercept administrated in patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis. An open phase IV trial.

PI

 

 

 

Selected Pub-Med Publications

  1. Predictors and long-term outcome in Greek adults with juvenile idiopathic arthritis: a 17-year continuous follow-up study.

           Dimopoulou D, Trachana M, Pratsidou-Gertsi P, Sidiropoulos P, Kanakoudi-Tsakalidou F, Dimitroulas T, Garyfallos A.

           Rheumatology (Oxford). 2017 Nov 1;56(11):1928-1938. doi: 10.1093/rheumatology/kex265

  1. Autoimmune Thrombotic Thrombocytopenic Purpura: Two rare cases associated with juvenile idiopathic arthritis and multiple sclerosis.

           Dimopoulou D, Dimosiari A., Mandala E, Dimitroulas T, Garyfallos A.

           Front Med (Lausanne). 2017 Jul 24;4:89. doi: 10.3389/fmed.2017.00089.eCollection 2017                  

  1. The role of nailfold capillaroscopy in the assessment of internal organ involvement in systemic sclerosis: A critical review

           Soulaidopoulos S, Triantafyllidou E, Garyfallos A, Kitas GD, Dimitroulas T

          Autoimmun Rev. 2017 Aug;16(8):787-795. doi: 10.1016/j.autrev.2017.05.019. Epub 2017 May 30. Review

  1. Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry.

          Guillevin L, Hunsche E, Denton CP, Krieg T, Schwierin B, Rosenberg D, Matucci-Cerinic M; DUO Registry Group.

          Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):71-80. Epub 2013 Jul 22.

  1. Investigation of juvenile idiopathic arthritis susceptibility loci: results from a Greek population.

           Dimopoulou DG, Zervou MI, Trachana M, Myrthianou E, Pratsidou-Gertsi P, Kardassis D, Garyfallos A, Goulielmos GN.

           Hum Immunol. 2013 Sep;74(9):1194-8. doi: 10.1016/j.humimm.2013.06.018. Epub 2013 Jun 15.

  1. Micro- and Macrovascular Treatment Targets in Scleroderma Heart Disease.

          Dimitroulas T, Giannakoulas G, Karvounis H, Garyfallos A, Settas L, Kitas GD.

         Curr Pharm Des. 2013 Apr 2. [Epub ahead of print]

  1. B-type nariuretic peptide in rheumatic diseases: a cardiac biomarker or a sophisticated acute phase reactant?

          Dimitroulas T, Giannakoulas G, Karvounis H, Garyfallos A, Settas L, Kitas G.

          Autoimmun Rev. 2012 Oct;11(12):837-43. doi:10.1016/j.autrev.2012.02.018. Epub 2012 Feb28. Review

  1. Clinical expression and morbidity of systemic lupus erythematosus during a post-diagnostic 5-year follow-up: a male:female comparison.

           Stefanidou S, Benos A, Galanopoulou V, Chatziyannis I, Kanakoudi F, Aslanidis S, Boura P, Sfetsios T, Settas L, Katsounaros M, 

           Papadopoulou D, Giamalis P, Dombros N, Chatzistilianou M, Garyfallos A.

           Lupus. 2011 Oct;20(10):1090-4. doi: 10.1177/0961203311403640. Epub 2011 Jun 23.

  1. Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis.

           Dimitroulas T, Giannakoulas G, Papadopoulou K, Sfetsios T, Karvounis H, Dimitroula H, Parcharidou D, Koliakos G, Garyfallos A, 

           Styliadis I, Settas L.

          Clin Rheumatol. 2010 Sep;29(9):957-64. doi: 10.1007/s10067-010-1494-3. Epub 2010 Jun 5.

  1. Primary adrenal lymphoma presenting as Addison’s disease. Case report and review of the literature.

           Kita M, Mandala E, Saratzis A, Venzi L, Venizelos I, Keryttopoulos P, Efstathiadou Z, Garyfallos A, Avramides A.

           Exp Clin Endocrinol Diabetes. 2008 Jun;116(6):363-5

  1. Brucellar spondylodiscitis: noncontiguous multifocal involvement of the cervical, thoracic, and lumbar spine.

           Raptopoulou A, Karantanas AH, Poumboulidis K, Grollios G, Raptopoulou-Gigi M, Garyfallos A. Clin Imaging. 2006 May-Jun;30(3):214-7.

  1. Anti-tumour necrosis factor therapy in ankylosing spondylitis. A need for guidelines.

          Kassimos DG, Garyfallos A, Delamere J, Whallett A, Kitas GD. 

          Rheumatology (Oxford). 2003 Mar;42(3):490. No abstract available.

  1. The relative proportions of secreted interleukin-2 and interleukin-10 determine the magnitude of rheumatoid arthritis T-cell proliferation to the recall antigen tuberculin purified protein derivative.

          Corrigall VM, Garyfallos A, Panayi GS.

          Rheumatology (Oxford). 1999 Dec;38(12):1203-7.

  1. The engineered human anti-tumor necrosis factor-alpha antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis.

           Choy EH, Rankin EC, Kassimos D, Vetterlein O, Garyfallos A, Ravirajan CT, Sopwith M, Eastell R, Kingsley GH, Isenberg DA,

           Panayi GS.J Rheumatol. 1999 Nov;26(11):2310-7.

  1. Evaluation of the renal mechanisms for urate homeostasis in uremic patients by probenecid and pyrazinamide test.

           Garyfallos A, Magoula I, Tsapas G.

           Nephron. 1987;46(3):273-80.

International Hellenic University © Copyright 2016 | Contact the webmaster of this site at This email address is being protected from spambots. You need JavaScript enabled to view it.
 

| Open Access Policy | Disclaimer | Contact the IHU | Sitemap | International Hellenic University, 14th km Thessaloniki-N. Moudania, 57001 Thermi, Greece |